A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 18 Aug 2017
At a glance
- Drugs Avelumab (Primary) ; Irinotecan; Paclitaxel
- Indications Gastric cancer
- Focus Registrational; Therapeutic Use
- Acronyms JAVELIN Gastric 300
- Sponsors EMD Serono
- 08 Aug 2017 Planned End Date changed from 30 Sep 2022 to 20 Sep 2022.
- 08 Aug 2017 Planned primary completion date changed from 31 Aug 2017 to 14 Sep 2017.
- 03 May 2017 Status changed from recruiting to active, no longer recruiting.